National Bank of Canada FI Boosts Stock Position in SPDR S&P Biotech ETF (NYSEARCA:XBI)

National Bank of Canada FI boosted its stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 11.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 15,986 shares of the exchange traded fund’s stock after buying an additional 1,589 shares during the period. National Bank of Canada FI’s holdings in SPDR S&P Biotech ETF were worth $1,579,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Castleark Management LLC grew its stake in shares of SPDR S&P Biotech ETF by 130.7% in the 3rd quarter. Castleark Management LLC now owns 115,580 shares of the exchange traded fund’s stock valued at $11,419,000 after buying an additional 65,490 shares during the period. Insigneo Advisory Services LLC lifted its stake in shares of SPDR S&P Biotech ETF by 12.6% in the 3rd quarter. Insigneo Advisory Services LLC now owns 2,751 shares of the exchange traded fund’s stock valued at $272,000 after purchasing an additional 308 shares during the last quarter. Kovitz Investment Group Partners LLC boosted its stake in SPDR S&P Biotech ETF by 0.4% during the third quarter. Kovitz Investment Group Partners LLC now owns 56,878 shares of the exchange traded fund’s stock worth $5,558,000 after buying an additional 218 shares during the period. Wellington Management Group LLP boosted its position in shares of SPDR S&P Biotech ETF by 66.8% during the 3rd quarter. Wellington Management Group LLP now owns 52,561 shares of the exchange traded fund’s stock worth $5,193,000 after purchasing an additional 21,049 shares during the period. Finally, Stevens Capital Management LP acquired a new stake in SPDR S&P Biotech ETF in the 3rd quarter valued at approximately $1,682,000.

SPDR S&P Biotech ETF Stock Down 0.8 %

NYSEARCA:XBI opened at $93.40 on Friday. SPDR S&P Biotech ETF has a 52 week low of $81.14 and a 52 week high of $105.47. The stock’s fifty day moving average is $98.05 and its two-hundred day moving average is $97.06. The stock has a market capitalization of $7.12 billion, a price-to-earnings ratio of 11.47 and a beta of 1.11.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.